{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:42Z","timestamp":1790409162992,"version":"4.1.0"},"reference-count":100,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2021-0031"],"award-info":[{"award-number":["2021-0031"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>T cell\u2013redirecting bispecific antibodies (BsAb) induce significant responses in heavily pretreated multiple myeloma. BsAbs are currently administered in a dose-dense manner until disease progression. However, continuous therapy is associated with safety concerns, including a high risk of infections and high costs. In addition, chronic exposure to BsAbs, and thus long-term T-cell stimulation, induces T-cell exhaustion, which may contribute to relapse. There is increasing evidence that the strategy of induction treatment followed by maintenance with longer intervals between BsAb doses, or limited treatment duration with cessation of therapy in patients who achieve deep remission, improves the balance between toxicity and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>There is increasing evidence that after initial debulking, less-frequent BsAb administration mitigates T-cell exhaustion and minimizes the potential for chronic or cumulative toxicity while maintaining durable clinical responses. In addition, specific patient subsets may experience an extended treatment-free period following fixed-duration treatment. Fixed-duration treatment may, therefore, decrease cumulative toxicities and the burden on patients and healthcare systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0124","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T13:12:12Z","timestamp":1727269932000},"page":"388-399","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["T Cell\u2013Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W.C.J.","family":"van de Donk","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"3Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"4Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2026041310165180700_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"2026041310165180700_bib2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2026041310165180700_bib6","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026041310165180700_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib9","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2026041310165180700_bib10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"2026041310165180700_bib11","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib12","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"suppl","key":"2026041310165180700_bib13","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib14","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2026041310165180700_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2023-182345","article-title":"Results from the completed dose escalation portion of the phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC\u00ae) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (MM)","volume":"142","author":"Madan","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310165180700_bib16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310165180700_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310165180700_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"2026041310165180700_bib19","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib20","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026041310165180700_bib21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib22","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026041310165180700_bib24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"2026041310165180700_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2026041310165180700_bib26","first-page":"20","article-title":"Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab","volume":"32","author":"Laheij","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026041310165180700_bib27","first-page":"S2152-2650:00174-5","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041310165180700_bib28","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2026041310165180700_bib29","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2023-187755","article-title":"Mechanisms of resistance and relapse with talquetamab in patients with relapsed\/refractory multiple myeloma from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"2026041310165180700_bib30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"2026041310165180700_bib31","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026041310165180700_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"2026041310165180700_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2026041310165180700_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood-2023-173550","article-title":"Longitudinal correlative profiles of responders, nonresponders, and those with relapse on treatment with teclistamab in the phase 1\/2 MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"2026041310165180700_bib35","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"2026041310165180700_bib36","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"key":"2026041310165180700_bib37","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026041310165180700_bib38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"2026041310165180700_bib39","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041310165180700_bib40","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026041310165180700_bib41","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib42","article-title":"Total immunotherapy: impact of bridging with bispecific antibodies on subsequent anti-BCMA CAR T cell therapy for relapsed\/refractory multiple myeloma","author":"Fandrei","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"Suppl 1","key":"2026041310165180700_bib43","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310165180700_bib44","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2023-189042","article-title":"The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in myeloma patients treated with BCMA bispecific antibodies","volume":"142","author":"Eisele","year":"2023","journal-title":"Blood"},{"key":"2026041310165180700_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"2026041310165180700_bib46","doi-asserted-by":"crossref","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026041310165180700_bib47","doi-asserted-by":"crossref","first-page":"101584","DOI":"10.1016\/j.xcrm.2024.101584","article-title":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026041310165180700_bib48","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib49","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"2026041310165180700_bib50","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"2026041310165180700_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib52","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"2026041310165180700_bib53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"2026041310165180700_bib54","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after gprc5d-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib55","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1182\/bloodadvances.2019000466","article-title":"Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies","volume":"3","author":"Cohen","year":"2019","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib56","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026041310165180700_bib58","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"2026041310165180700_bib60","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"2026041310165180700_bib62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026041310165180700_bib63","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"2026041310165180700_bib64","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib65","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","article-title":"Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026041310165180700_bib66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310165180700_bib67","unstructured":"Oncologic drugs advisory committee meeting (fda.gov). [cited 2024 Jul 22]: Available from:https:\/\/www.fda.gov\/media\/176988\/download."},{"key":"2026041310165180700_bib68","first-page":"blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"2026041310165180700_bib69","article-title":"What is optimal duration of therapy for bispecifics? 5th immune effector cell therapies in multiple myeloma workshop","author":"van de Donk","year":"2024"},{"key":"2026041310165180700_bib70","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2026041310165180700_bib71","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"2026041310165180700_bib72","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2026041310165180700_bib73","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-014-1525-z","article-title":"ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells","volume":"63","author":"Bossi","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2026041310165180700_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology"},{"key":"2026041310165180700_bib75","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.V128.22.2096.2096","article-title":"New insights into the mechanism of action (MoA) of first-in-class IgG-based bcma T-cell bispecific antibody (TCB) for the treatment of multiple myeloma (MM)","volume":"128","author":"Moreno","year":"2016","journal-title":"Blood"},{"key":"2026041310165180700_bib76","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib77","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026041310165180700_bib78","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.HS9.0000844444.27744.38","article-title":"P389: bispecific antibodies activate autologous leukemia-reactive T cells in acute myeloid leukemia","volume":"6","author":"B\u00f6hm","year":"2022","journal-title":"HemaSphere"},{"key":"2026041310165180700_bib79","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026041310165180700_bib80","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2326-6066.CIR-19-0518","article-title":"A PSMA-targeting CD3 bispecific antibody induces antitumor responses that are enhanced by 4-1BB costimulation","volume":"8","author":"Chiu","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2026041310165180700_bib81","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.4161\/hv.26065","article-title":"The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting","volume":"9","author":"Atanackovic","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2026041310165180700_bib82","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310165180700_bib83","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-016-2449-0","article-title":"A phase I trial of the trifunctional anti Her2 \u00d7 anti CD3 antibody ertumaxomab in patients with advanced solid tumors","volume":"16","author":"Haense","year":"2016","journal-title":"BMC Cancer"},{"key":"2026041310165180700_bib84","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"2026041310165180700_bib85","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib86","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026041310165180700_bib87","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","article-title":"OA-05 efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses","volume":"23","author":"Harrison","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041310165180700_bib88","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"2026041310165180700_bib89","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S2152-2650(23)01641-5","article-title":"P-023 Talquetamab, a G protein\u2013coupled receptor family C group 5 member D \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1","volume":"23","author":"Krishnan","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041310165180700_bib90","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041310165180700_bib91","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib92","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"2026041310165180700_bib93","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"2026041310165180700_bib94","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"key":"2026041310165180700_bib95","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"key":"2026041310165180700_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1574884713666180518102514","article-title":"Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-hodgkin lymphoma","volume":"13","author":"Hijazi","year":"2018","journal-title":"Curr Clin Pharmacol"},{"issue":"suppl","key":"2026041310165180700_bib97","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","article-title":"Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Rodriguez Valdes","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041310165180700_bib98","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","article-title":"An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood"},{"key":"2026041310165180700_bib99","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","article-title":"Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model","volume":"17","author":"Mandikian","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026041310165180700_bib100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0124\/3500860\/bcd-24-0124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0124\/3502630\/bcd-24-0124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/6\/388\/3509473\/bcd-24-0124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/6\/388\/3509473\/bcd-24-0124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:17:10Z","timestamp":1776089830000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/6\/388\/749224\/T-Cell-Redirecting-Bispecific-Antibodies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":100,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,12]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0124","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}